Remission of extranodal NK/T-cell lymphoma, nasal type, after SARS-CoV-2 vaccination

Br J Haematol. 2023 Feb;200(3):273. doi: 10.1111/bjh.18496. Epub 2022 Oct 5.

Authors

Mengxiang Chen^{1

2}, Fu Ouyang³, Tao Wu^{1

2}, Yunfei Hu^{1

2}, Yan Du², Yunhong Huang^{1

2}

Affiliations

¹ Department of Oncology, the Affiliated Hospital, Guizhou Medical University, Guiyang, China.
² Department of Oncology, the Affiliated Cancer Hospital, Guizhou Medical University, Guiyang, China.
³ Department of Neurology, the Affiliated Hospital, Guizhou Medical University, Guiyang, Guizhou, China.

No abstract available

MeSH terms

COVID-19 Vaccines
COVID-19* / prevention & control
Humans
Lymphoma, Extranodal NK-T-Cell* / pathology
Lymphoma, Extranodal NK-T-Cell* / therapy
Nose Neoplasms*
SARS-CoV-2
Vaccination

Substances

COVID-19 Vaccines